Aurobindo Pharma Q2 net profit up 26% to ₹805.65 crore
Consolidated total revenue from operations during the period under review stood at ₹6,483.44 croreThe company said it received final approval for 10 ANDAs (abbreviated new drug applications) from USFDA
PremiumAurobindo Pharma Ltd on Wednesday reported a 26% increase in consolidated net profit at ₹805.65 crore in the second quarter ended September.
The company had posted a consolidated net profit of ₹639.53 crore in the same quarter last fiscal, Aurobindo Pharma said in a regulatory filing.
Consolidated total revenue from operations during the period under review stood at ₹6,483.44 crore as against ₹5,600.47 crore in the corresponding quarter last fiscal, it added.
Commenting on the company's performance Aurobindo Pharma Managing Director N Govindarajan said: "We continue to perform well across all our key geographies and segments to report a consistent set of earnings."
He further said: "On our endeavour towards our differentiated products basket, we are happy to state that we have completed phase I clinical trials for our first biosimilar and started trials for three more products. We reiterate that we are committed to resolving all pending regulatory issues."
During the second quarter, the company said its US formulation revenue stood at ₹3,189.8 crore as against ₹2,835.5 crore in same period last fiscal, a growth of 12.5%, while Europe formulation revenue was at ₹1,514.8 crore, a growth of 8.1% from the year-ago quarter.
The company said it received final approval for 10 ANDAs (abbreviated new drug applications) from USFDA.
Its board has also approved a second interim dividend of 125% at ₹1.25 per equity share of Re 1 for the financial year 2020-21.
"Exciting news! Mint is now on WhatsApp Channels 🚀 Subscribe today by clicking the link and stay updated with the latest financial insights!" Click here!
This story has been published from a wire agency feed without modifications to the text. Only the headline has been changed.
